Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 µM).
|Number of pages||6|
|Journal||Journal of Medical Virology|
|Publication status||Published - 2021 Mar|
Bibliographical noteFunding Information:
The pathogen resource (NCCP43326) for this study was provided by the National Culture Collection for Pathogens. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF‐2017M3A9G6068245 and NRF‐2020M3E9A1041756).
© 2020 Wiley Periodicals LLC
All Science Journal Classification (ASJC) codes
- Infectious Diseases